利培酮与奋乃静治疗64例女性精神分裂症对照研究

Comparative study between Risperidone and Perphenazine in the treatment of female patients with schizophrenia

目的:评价利培酮和奋乃静治疗女性精神分裂症的疗效和不良反应。方法:对68例女性精神分裂症患者随机分为两组,分别给予利培酮与奋乃静治疗,疗程8周。用阳性与阴性症状量表(PANSS)与不良反应量表(TESS)评定疗效和不良反应。结果:两组总的疗效差异无显著性(P>0.05),但利培酮起效较快;且在治疗阴性症状方面,以利培酮显著较好(P<0.05)。利培酮组不良反应较奋乃静组少,其中静坐不能、心动过速、震颤、视物模糊显著少于奋乃静组(P<0.05)。结论:利培酮是一种安全有效的抗精神病药。

Objective：To detect the clinical efficacy and side effects of Risperidone and Perphenazine in the treatment of female schizophrenic patients. Methods：68 female schizophrenic patients have been divided into Risperidone group and Perphenazine group randomly to treat for 8 weeks. Positive and negative syndrome scale （PANSS） and treatment emergent symptom scale （TESS） were used to evaluate the efficacy and side effects respectively. Results： There were no significant difference between two groups （ P 〉 0.05）. However, Risperidone took effect more quickly But, significant difference were found between two groups in the reduction rate of scale about negative symptoms （P 〈 0.05）. Patients in Risperidone group reported much fewer side effects than those in Perphenazine group, especially in the items of skathisia, tachycardua, tremor, and blur sight on TESS （P 〈 0.05 ）. Conclusions： Risperidone is an effective antipsyshotic drug with fewer side effects.